BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dynogen Pharmaceuticals, Inc. 

52 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-839-5100 Fax: 781-839-5200


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Dynogen Pharmaceuticals, Inc. Files for Bankruptcy 2/25/2009 8:06:27 AM    More...
Dynogen Pharmaceuticals, Inc. Presents Results of Its Positive Phase 2 IBS-d Study with DDP225 5/20/2008 6:08:12 AM    More...
Dynogen Pharmaceuticals, Inc. to Present Positive Clinical Data for DDP225 and DDP733 4/30/2008 6:35:17 AM    More...
Apex Bioventures (PEX) and Dynogen Pharmaceuticals, Inc. Mutually Terminate Merger Agreement 4/17/2008 9:54:46 AM    More...
Apex Bioventures (PEX) and Dynogen Pharmaceuticals, Inc. Announce Definitive Merger Agreement 2/6/2008 8:51:45 AM    More...
Dynogen Pharmaceuticals, Inc. Expands DDP225 Patent Estate 1/16/2008 8:30:21 AM    More...
Dynogen Pharmaceuticals, Inc. Announces Positive Results in Phase 2 IBS-d Study 12/17/2007 9:03:37 AM    More...
Dynogen Pharmaceuticals, Inc.'s Prokinetic Drug, DDP733, Enters Phase 2b for Irritable Bowel Syndrome with Constipation 11/8/2007 12:14:16 PM    More...
Dynogen Pharmaceuticals, Inc.'s Prokinetic Drug, DDP733, Enters Phase 2b for Irritable Bowel Syndrome with Constipation 11/8/2007 10:02:16 AM    More...
Dynogen Pharmaceuticals, Inc.'s Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study 10/15/2007 11:10:17 AM    More...
123